PAK1 and hepatocellular carcinoma: Sorafenib treatment induces mitochondrial dysfunction in human hepatocellular carcinoma cells (SK-Hep1 and Huh7), activating the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic (PI3K)-Rac family small GTPase 1 (RAC1)-p21 (RAC1) activated kinase 1 (PAK1) pathway-dependent macropinocytosis, thereby imparting ferroptosis resistance [184].